This study revealed that ERBB3 was a key resistance factor driving limited efficacy to sequential regorafenib, but also an effective therapeutic target whose inhibition enhanced regorafenib sensitivity after sorafenib or lenvatinib resistance.
Tao et al. (Tue,) studied this question.